Astrazeneca Says Got Updated Guidelines on Stemi
AstraZeneca (NYSE: AZN) announced today that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for use of the oral antiplatelet (OAP) medicine BRILINTA^® (ticagrelor) tablets in patients with ST-elevation myocardial infarction (STEMI) managed invasively.^1 With this latest guidelines update, BRILINTA is included in more than 10 major acute coronary syndrome (ACS) treatment guidelines globally.^1-11
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.